Register Login

Axsome Therapeutics Inc (AXSM)

  • Event
  • May 31, 2022, 11:06 UTC

(90% Positive) Axsome Therapeutics, Inc. (AXSM) Announces Enrollment Update for option Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 10:40 p.m.

    📋 Axsome Therapeutics, Inc. (AXSM) - Clinical Trial Update

    Filing Date: 2022-05-31

    Accepted: 2022-05-31 07:06:25

    Event Type: Clinical Trial Update

    Event Details:

    Axsome Therapeutics Inc (AXSM) Announces Clinical Trial Update Axsome Therapeutics Inc (AXSM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: option, Dean
    • Diseases/Conditions: Clinical & Translational Research
    • Clinical Stage: Phase 3, Phase 3 Trial
    • Collaboration: Clinical & Translational Research

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Axsome Therapeutics Inc
    • CIK: 0001579428
    • Ticker Symbol: AXSM
    • Period End Date: 2022-05-31
    • Document Type: 8-K

Search

News categories